{
    "eid": "2-s2.0-85148907631",
    "title": "Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation",
    "cover-date": "2023-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmaceutical Science",
            "@code": "3003",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "Drug",
        "Global health",
        "Nitrosamine",
        "Nitrosation",
        "Risk mitigation"
    ],
    "authors": [
        "Bodin Tuesuwan",
        "Vorasit Vongsutilers"
    ],
    "citedby-count": 1,
    "ref-count": 107,
    "ref-list": [
        "Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs Volumes 1 to 42.7",
        "The contamination of valsartan and other sartans, Part 1: new findings",
        "Critical analysis of drug product recalls due to nitrosamine impurities",
        "N-Nitrosodimethylamine (NDMA) formation from ranitidine impurities: possible root causes of the presence of NDMA in ranitidine hydrochloride",
        "Temperature-dependent formation of N-nitrosodimethylamine during the storage of ranitidine reagent powders and tablets",
        "Insight into the formation of N-nitrosodimethylamine in metformin products",
        "Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products",
        "14th Report on Carcinogens",
        "N-Nitrosodimethylamine contamination in the metformin finished products",
        "Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite",
        "International regulatory collaboration on the analysis of nitrosamines in metformin-containing medicines",
        "The nitrosamine contamination of drugs, part 3: quantification of 4-methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS",
        "Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data",
        "Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential",
        "Use of less-than-lifetime (LTL) durational limits for nitrosamines: case study of N-nitrosodiethylamine (NDEA)",
        "Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study",
        "Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research",
        "Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma",
        "Evaluating the effects of genetic variants of DNA repair genes using cytogenetic mutagen sensitivity approaches",
        "Risk assessment for nitrosated pharmaceuticals: a future perspective in drug development",
        "Artifactual degradation of secondary amine-containing drugs during accelerated stability testing when saturated sodium nitrite solutions are used for humidity control",
        "N-nitrosation in the absence of nitrosating agents in pharmaceuticals?",
        "Pathways for N-nitroso compound formation: secondary amines and beyond",
        "Formation of N-nitroso compounds: Chemistry, kinetics, and in vivo occurrence",
        "Reaction of secondary and tertiary amines with nitric oxide in the presence of oxygen",
        "Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water",
        "Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives",
        "A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists",
        "Determination of genotoxic azide impurity in cilostazol API by ion chromatography with matrix elimination",
        "Chapter 8 - FDA approved six-membered ring fused pyrimidine-based derivatives",
        "NDMA formation from amine-based pharmaceuticals - impact from prechlorination and water matrix",
        "N-nitrosodimethylamine (NDMA) contamination of ranitidine products: a review of recent findings",
        "Chloramination of nitrogenous contaminants (pharmaceuticals and pesticides): NDMA and halogenated DBPs formation",
        "Demonstration of 20 pharmaceuticals and personal care products (PPCPs) as nitrosamine precursors during chloramine disinfection",
        "NDMA formation kinetics from three pharmaceuticals in four water matrices",
        "Ranitidine: a proposed mechanistic rationale for NDMA formation and a potential control strategy",
        "Trace aldehydes in solid oral dosage forms as catalysts for nitrosating secondary amines",
        "Ranitidine\u2014investigations into the root cause for the presence of N-nitroso-N,N-dimethylamine in ranitidine hydrochloride drug substances and associated drug products",
        "Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility",
        "A nitrite excipient database: a useful tool to support N-nitrosamine risk assessments for drug products",
        "Nitrites as precursors of N-nitrosation in pharmaceutical samples - a trace level analysis",
        "Determination of dimethylamine and nitrite in pharmaceuticals by ion chromatography to assess the likelihood of nitrosamine formation",
        "Degradation of aged nitrocellulose investigated by thermal analysis and chemiluminescence",
        "Evaluating nitrosamines from elastomers in pharmaceutical primary packaging",
        "Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography\u2013tandem mass spectrometry",
        "NDMA analytics in metformin products: comparison of methods and pitfalls",
        "HS-SPME-GC-MS as an alternative method for NDMA analysis in ranitidine products",
        "A cautionary tale: quantitative LC-HRMS analytical procedures for the analysis of N-nitrosodimethylamine in metformin",
        "A substructure-based screening approach to uncover N-nitrosamines in drug substances",
        "The landscape of potential small and drug substance related nitrosamines in pharmaceuticals",
        "Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtained",
        "Developing structure-activity relationships for N-nitrosamine activity",
        "What makes a potent nitrosamine? Statistical validation of expert-derived structure\u2013activity relationships",
        "Reaction of irbesartan with nitrous acid produces irbesartan oxime derivatives, rather than N-nitrosoirbesartan",
        "Clues to the non-carcinogenicity of certain N-nitroso compounds: role of alkylated DNA bases",
        "In silico assessment of genotoxicity. Combinations of sensitive structural alerts minimize false negative predictions for all genotoxicity endpoints and can single out chemicals for which experimentation can be avoided"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Merck KGaA",
        "Chulalongkorn University"
    ]
}